Search results
Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
Alaska Superstation· 2 days agoSeniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted...
Earnings call: Aptose Biosciences targets AML treatment with tuspetinib By Investing.com
Investing.com· 1 day agoAptose Biosciences (NASDAQ:APTO) has focused its efforts on developing tuspetinib as part of a novel...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 10 minutes agoMP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being preparedRadio-DARPin Therapy (RDT): Lead DLL3 candidate advancing into
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA)...
WTRF Wheeling· 8 hours agoMoleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses ...
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
CBS 47 Fresno· 2 days agoAs of May 9, 2024, Ryvu's cash position was $59.0M, inclusive of the first tranche of €8M in venture debt from the EIB, obtained in March. This cash position, and other secured funding sources ...
Study: Older Adults With Aggressive Blood Cancer A | Newswise
Newswise· 7 days agoStandard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over...
Bio-Path Holdings Inc (BPTH) Q1 2024 Earnings Call Transcript Hi
Guru Focus· 13 hours agoNet Loss: $3.2 million for Q1 2024, improved from $5.3 million in Q1 2023.Earnings Per Share (EPS):...
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology...
FOX 23 News Albany· 2 days agoUpdated data from the Phase I trial of RVU120 in patients with relapsed/refractory acute myeloid ...
Q1 2024 Bio Path Holdings Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 16 hours agoTurning now to the progress we have made with our lead product candidate, prexigebersen. As you know, last year, we reported positive interim results from Stage 2 of our Phase 2 clinical trial ...
Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and...
WJTV Jackson· 3 days agoIomab-B and Actimab-A are the only targeted radiotherapies in development for patients with relapsed/refractory acute myeloid leukemia
